Recent 8-K filings for CARM

• December 5, 2025, 6:59 PM ET other material materiality 0.90 negative item 3.01item 5.02

  Carisma voluntarily delisting from Nasdaq, terminating SEC reporting; appoints new CEO for wind-down

  Board approved voluntary delisting from Nasdaq; Form 25 expected Dec 10; delisting effective 10 days later.

• October 15, 2025, 7:59 PM ET leadership materiality 0.90 negative item 5.02item 9.01

  Carisma Therapeutics terminates CEO (eff. Nov 15) and CSO; three directors resign

  CEO Steven Kelly terminated without cause, effective Nov 15, 2025; gets $624K severance plus $299,948 prorated bonus and health payments.

• October 9, 2025, 7:59 PM ET other material materiality 1.00 negative item 3.01 ◈ Listing & Compliance Notices

  Carisma Therapeutics to be delisted from Nasdaq on Oct 13; expects to wind down operations

  Received Nasdaq delisting letter; common stock suspended from trading effective Oct 13, 2025; no appeal planned.

• September 18, 2025, 7:59 PM ET other material materiality 0.95 negative item 1.01item 1.02item 8.01

  Carisma terminates merger with OrthoCellix, receives $4M from Moderna, expects wind-down

  Moderna pays $4M one-time to eliminate all future milestones, royalties, and research costs under the 2022 collaboration; licenses become fully paid-up and perpetual.

• August 29, 2025, 7:59 PM ET M&A materiality 0.70 neutral item 1.01item 3.02item 5.01item 5.02item 8.01item 9.01

  Carisma enters $5M subscription deal with Ocugen; Nasdaq deadline extended to Oct 21

  Subscription agreement with Ocugen for $5M private placement as part of concurrent $25M financing.

• August 8, 2025, 7:59 PM ET other material materiality 0.50 neutral item 5.07

  Carisma stockholders approve reverse stock split at ratio of 1:10 to 1:50

  Stockholders adopted reverse split amendment; board has sole discretion to set exact ratio (1:10 to 1:50) and timing.

• July 15, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 3.01

  Carisma receives Nasdaq delisting notice for bid price non-compliance; schedules Aug 5 reverse split vote

  Nasdaq notified Carisma on July 9, 2025 that failure to regain bid price compliance is an additional delisting basis.

• June 23, 2025, 7:59 PM ET M&A materiality 0.90 negative item 1.01item 7.01item 9.01

  Carisma to merge with OrthoCellix; pre-merger holders to own ~10% of combined company

  Carisma (CARM) enters merger with Ocugen subsidiary OrthoCellix; Merger Sub to merge into OrthoCellix, which becomes wholly owned subsidiary.

• June 12, 2025, 7:59 PM ET other material materiality 0.70 neutral item 8.01

  Carisma Therapeutics secures Nasdaq listing extension with transfer to Capital Market, strict conditions to Oct 7, 2025

  Nasdaq Panel granted exception; listing transferred to Nasdaq Capital Market effective June 12, 2025.

• April 16, 2025, 7:59 PM ET other material materiality 0.75 negative item 3.01

  Carisma receives Nasdaq delisting notice for MVLS, MVPHS, bid price non-compliance

  Nasdaq notified Carisma on April 10, 2025, of delisting for failing to maintain $50M MVLS by April 8, 2025 compliance deadline.

• January 13, 2025, 6:59 PM ET other material materiality 0.55 neutral item 8.01

  Carisma updates pipeline: CT-1119 Phase 1 start H1 2025, liver fibrosis IND in 2026

  CT-1119 (mesothelin-targeted CAR-Monocyte) Phase 1 trial with tislelizumab in solid tumors expected to start H1 2025.

• January 10, 2025, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

  Carisma Therapeutics receives Nasdaq bid price deficiency notice; has until July 7, 2025 to regain compliance

  Received Nasdaq notice on Jan 6, 2025 for non-compliance with minimum bid price of $1.00 per share.

• December 26, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02item 9.01

  Carisma Therapeutics appoints interim VP of Finance, principal accounting officer

  Natalie McAndrew appointed interim VP of Finance effective Jan 1, 2025.

• December 9, 2024, 6:59 PM ET other material materiality 0.80 negative item 2.05item 5.02item 8.01

  Carisma Therapeutics reduces workforce by 34%, terminates CFO, discontinues lead candidate CT-0525

  Reduction of 23 employees (34% of workforce); expects ~$2.7M in one-time termination costs, substantially complete by Q1 2025.

• November 7, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Carisma Q3 net loss $12.7M; cash $26.9M; CT-0525 initial data expected Q1 2025

  Net loss of $12.7M in Q3 2024 vs $21.4M in Q3 2023; R&D expenses fell to $11.3M from $19.6M.

• October 30, 2024, 7:59 PM ET leadership materiality 0.25 neutral item 5.02 ◈ executive_change ×2

  Carisma Therapeutics announces director resignation and appointment of Sohanya Cheng

  Michael Torok resigns from board effective Oct 31, 2024; cites other professional commitments, no disagreement.

• October 11, 2024, 7:59 PM ET regulatory materiality 0.65 negative item 3.01

  Carisma Therapeutics receives Nasdaq deficiency notice for market value below $50M

  Nasdaq notified Carisma on Oct 10, 2024 that MVLS fell below $50M minimum requirement.

• August 8, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Carisma Therapeutics Q2 2024 net loss $11.2M; CT-0525 data expected by year-end

  Net loss improved to $11.2M in Q2 2024 from $19.9M in Q2 2023; R&D expenses declined to $15.3M.

• July 9, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Carisma reports 75% ctDNA reduction in HER2 3+ patients in Phase 1 CT-0508 trial

  75% (6/8) evaluable HER2 3+ patients had ctDNA reduction (median 81%, range 33%-93%); no reduction in 5 HER2 2+ patients.

• July 2, 2024, 7:59 PM ET other material materiality 0.75 negative item 2.05

  Carisma terminates Novartis manufacturing deal for CT-0508; pays $4M fee, suspends Phase 1 enrollment

  Terminated Manufacturing and Supply Agreement with Novartis for CT-0508; effective July 31, 2024.

• July 1, 2024, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change ×4

  Carisma Therapeutics appoints Thorell and Scadden to board; Hodits and Odlander resign

  Regina Hodits and Björn Odlander resigned from board effective June 30, 2024, citing other professional commitments, not disagreements.

• June 27, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Carisma nominates first in vivo CAR-M candidate under Moderna collab; $2M milestone triggered

  Development candidate targets Glypican-3 for solid tumors, including hepatocellular carcinoma (HCC).

• June 14, 2024, 7:59 PM ET other material materiality 0.50 neutral item 5.02

  Carisma grants retention options: 125K shares CEO, 85K each CFO/CSO, vesting over 2 years

  CEO Steven Kelly receives option for 125,000 shares; CFO Richard Morris and CSO Michael Klichinsky each get 85,000 shares.

• June 14, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Carisma Therapeutics holds annual meeting; all proposals approved by shareholders

  Directors John Hohneker, M.D. and Michael Torok elected with 16.7M and 16.0M votes for respectively.

• May 9, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01 ◈ Earnings Releases

  Carisma Therapeutics Q1 net loss $19.0M; cash $56.5M; lead candidate CT-0525 prioritized

  Net loss $19.0M for Q1 2024 vs $24.6M in Q1 2023; R&D expenses $17.5M.

• April 10, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Carisma reports preliminary Phase 1 data for CT-0508; 40.7% target lesion reduction in monotherapy

  In 14 monotherapy patients, 40.7% of target lesions reduced in size on ≥1 scan across all anatomic sites.

• April 1, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01 ◈ Earnings Releases

  Carisma Therapeutics reports $86.9M net loss; prioritizes CT-0525, cuts workforce 37%

  Cash of $77.6M as of Dec 31, 2023, expected to fund operations into Q3 2025 after restructuring.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.70 · Most common event other_material

2 positive 13 negative 12 neutral

source · CARM on sec.gov